Mycophenolate mofetil in patients with refractory systemic autoimmune myopathies: case series

Table 1 General features of 17 refractory idiopathic systemic autoimmune myopathies

No	Disease	Disease (years)	Treatment			Activity		CPK (U/L)		Prednisone (mg/day)*
No	Disease	Disease (years)	Previous	Immediately Before MMF	Current	Initial	6 months after MMF treatment	Initial	6 months after MMF treatment	Inicial	6 months after MMF treatment
1	PM	2	MP,Pred,Aza,CYC	CP	CP, MMF	P	P	95	130	5.0	20.0
2	DM	2	Pred,Aza,MTX,CYC	AZA	MMF	P	Remission	48	66	15.0	5.0
3	ASS	1	MP,Pred,IVIg,Aza,MTX,CYC	CYC	MMF	Mu,C,P	Mu	242	139	20.0	10.0
4	ASS	2	Pred,Aza,MTX,CYC	MTX	MTX, MMF	Mu,C	Remission	167	200	10.0	5.0
5	DM	8	Pred,AM,Aza,CP,RTX,Tac	AM,Tac	AM, Tac, MMF	Mu,C	C	141	53	15.0	20.0
6	DM	3	Pred,Aza,MTX	AZA	AZA, MMF	Mu,C	Mu	268	148	15.0	7.5
7	DM	2	MP,Pred,Aza,MTX	MTX	MMF	Mu	Mu	40	20	50.0	30.0
8	DM	6	MP,Pred,Aza,MTX,CP	MTX,CP	CP, MMF	Mu	Mu	249	2120	10.0	15.0
9	PM	6	MP,Pred,Aza,MTX	AZA	AZA, MMF	Mu	Mu	1534	3517	5.0	0
10	DM	1	MP,Pred,Aza,CYC,RTX	RTX	RTX, MMF	Mu	Mu	215	255	15.0	2.5
11	PM	1	Pred,Aza,MTX	-	MMF	Mu	Mu	118	205	60.0	5.0
12	DM	1	MP,AM,AZA,MTX	AZA	MMF	Mu	Mu	35	30	40.0	5.0
13	DM	1	MP,Pred,AZA,MTX	MTX	MTX, MMF	Mu	Remission	245	257	10.0	0
14	DM	5	MP,AM,AZA,MTX,CP	AZA,CP	AZA, MMF	Mu	Mu	858	268	10.0	0
15	DM	1	Pred,AZA,CYC	-	MMF	C,P	C	114	138	15.0	5.0
16	DM	1	MP,Pred,MTX	MTX	MTX, MMF	C	Remission	100	80	12.5	5.0
17	CADM	3	Pred,AZA,MTX,LFN,CYC	AZA,LFN	AZA, MMF	C	C	79	95	60.0	2.5
		2.0 (1.0-4.0)								15.0 (10.0-30.0)	5.0 (2.5-12.5)

AM antimalarials, ASS anti-synthetase syndrome, AZA azathioprine, CPK creatine phosphokinase, CP cyclosporine, C cutaneous, CADM clinically amyopathic dermatomyositis, CYC cyclophosphamide, DM dermatomyositis, F female, IVIg intravenous human immunoglobulin, LFN leflunomide, M male, MP methylprednisolone pulse therapy, MTX methotrexate, Mu muscular, PM polymyositis, P pulmonary, Pred prednisone, RTX rituximab, Tac tacrolymus
^*Pred: current vs. 6 months: P = 0.005

ISSN: 2523-3106